Skip to content
lifestyle.independent.mk
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Orvida Pharma Ltd
Orvida Pharma Announces FDA Acceptance of KM-023 (ontivatrep) into Rare Disease Evidence Principles Process for Olmsted Syndrome
October 14, 2026
Orvida Pharma Announces Interim Financing Led by Recordati to Advance Ontivatrep Development for Rare Genetic Skin Diseases
September 15, 2026
Orvida Pharma to Present Functional Endpoint Development Data in Rare Palmoplantar Skin Disorders at the 83rd Annual Meeting of the Society for Investigative Dermatology and the 2026 Epidermal Differentiation Disorders Symposium
May 22, 2026